Sanofi: positive data for hemophilia in children
The once-weekly dose achieves sustained levels of factor VIII expression in these patients, and confers highly effective protection against bleeding, without leading to the development of factor VIII inhibitors.
Altuviiio is approved for routine prophylaxis, on-demand treatment of bleeding episodes and peri-operative (surgical) management of adults and children with hemophilia A.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction